Vor Biopharma (NASDAQ:VOR) Stock Breaks Above Fifty Day Moving Average – Should You Sell?

by · The Markets Daily

Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report) passed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $20.82 and traded as high as $21.74. Vor Biopharma shares last traded at $20.91, with a volume of 967,944 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on VOR shares. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday. Citigroup upgraded shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, October 15th. Wedbush boosted their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. Weiss Ratings upgraded shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 14th. Finally, William Blair began coverage on shares of Vor Biopharma in a report on Wednesday, October 21st. They set an “outperform” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Get Our Latest Stock Analysis on Vor Biopharma

Vor Biopharma Price Performance

The business’s 50 day moving average is $20.75 and its 200-day moving average is $17.33.

Vor Biopharma (NASDAQ:VOR – Get Free Report) last issued its earnings results on Friday, October 30th. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.64). On average, equities analysts anticipate that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in Vor Biopharma during the 3rd quarter worth approximately $58,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Vor Biopharma by 25.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company’s stock valued at $198,000 after acquiring an additional 2,171 shares in the last quarter. Engineers Gate Manager LP grew its position in Vor Biopharma by 37.5% during the 2nd quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock worth $680,000 after acquiring an additional 10,071 shares during the last quarter. Braidwell LP grew its position in Vor Biopharma by 22.8% during the 2nd quarter. Braidwell LP now owns 573,104 shares of the company’s stock worth $10,551,000 after acquiring an additional 106,330 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in Vor Biopharma in the 2nd quarter worth about $499,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

(Get Free Report)

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.

Featured Articles